BofA Securities Downgrades Candel Therapeutics Inc. (CADL) to Neutral
Tweet
Share
E-mailGet Alerts CADL Hot Sheet
Price: $12.35 -8.52%
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 4 | New: 11
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 4 | New: 11
Join SI Premium – FREE
BofA Securities analyst Alec Stranahan downgraded Candel Therapeutics Inc. (NASDAQ: CADL) from Buy to Neutral with a price target of $7.00 (from $13.00).
For an analyst ratings summary and ratings history on Candel Therapeutics Inc. click here. For more ratings news on Candel Therapeutics Inc. click here.
Shares of Candel Therapeutics Inc. closed at $5.86 yesterday.
You May Also Be Interested In
- JPMorgan Downgrades Limbach Holdings (LMB) to Underweight
- Universal Store Holdings (UNI:AU) PT Raised to AUD12.96 at Citi
- Trial Holdings Inc (141A:JP) PT Raised to JPY5,000 at Citi
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
